Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

开始日期2024-03-20

申办/合作机构

Bayer AG

[+3]

NCT05658497

/ RecruitingN/A

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries).
The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

开始日期2023-10-27

申办/合作机构

Biogen, Inc.

PACTR202205508723236

/ Suspended临床3期IIT

A multi-centre, placebo-controlled studyof interferon beta-1a in high risk COVID-19 outpatients (InterCoV)

开始日期2022-05-15

申办/合作机构-

100 项与干扰素β-1a(Biogen, Inc.) 相关的临床结果

登录后查看更多信息

100 项与干扰素β-1a(Biogen, Inc.) 相关的转化医学

登录后查看更多信息

100 项与干扰素β-1a(Biogen, Inc.) 相关的专利（医药）

登录后查看更多信息

1,507

项与干扰素β-1a(Biogen, Inc.) 相关的文献（医药）

2025-05-01·NATURE IMMUNOLOGY

Interferon-β treatment restores myeloid function and reverses immunosuppression in sepsis

Article

2025-03-01·JOURNAL OF NEUROLOGY

A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies

Article

作者: Balshi, Alexandra ; Manning, Nova ; Leuenberger, Grace ; Baber, Ursela ; Sloane, Jacob A ; Dempsey, John

BACKGROUND AND OBJECTIVE:

People with multiple sclerosis (PwMS) may be at an increased risk of surgical site infections (SSIs). However, the role of specific MS disease-modifying therapies (DMTs) in modulating this risk remains underexplored.

METHODS:

The FDA Adverse Event Reporting System (FAERS) was used to investigate if MS DMTs are associated with disproportionally higher SSI reporting compared to other FAERS medications for individuals of all ages and those over the age of 50.

RESULTS:

We identified 769 reports of SSIs across MS DMTs (352 in PwMS aged 50 or older) and 21 SSI-associated deaths. A pooled analysis of all DMTs revealed increased risks of SSIs (reporting odds ratio [ROR] of 1.95, 95% confidence interval [CI] 1.80-2.12) for all age groups and for those 50 or older (ROR of 2.58, 95% CI 2.27-2.92). For both age groups, ocrelizumab and interferon beta-1a met Evan's threshold for disproportionally high SSI reporting compared to all other FAERS medications.

CONCLUSION:

MS DMTs are collectively associated with disproportionately high SSI reporting, especially for PwMS over the age of 50, with ocrelizumab and interferon beta-1a increasing SSI reporting risk in both age groups. These findings reveal a need to take extra precautions when caring for PwMS in a surgical setting, such as engaging wound care teams to minimize SSI risk.

2025-03-01·Multiple Sclerosis and Related Disorders

Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials

Article

作者: Bonati, Ulrike ; Hartung, Hans-Peter ; Koendgen, Harold ; Pei, Jinglan ; Benedict, Ralph Hb ; Overell, James ; Miller, Aaron ; Wang, Qing ; Cohan, Stanley ; Bernasconi, Corrado ; Kappos, Ludwig ; Dahlke, Frank

BACKGROUND:

Cognitive impairment is a well-recognized symptom of multiple sclerosis (MS) that can manifest early in the disease course. Deficits in cognitive function can have a major impact on daily life. However, cognitive decline is often under-examined in clinical trials and clinical practice due to lack of adequate data. The objective of this study was to examine the longitudinal effect of ocrelizumab vs interferon beta (IFNβ)-1a on cognitive impairment in 2 phase 3 studies in relapsing MS (RMS).

METHODS:

The pooled population of participants with RMS (n = 1656) from the OPERA I/II clinical trials received subcutaneous IFNβ-1a (44 μg; n = 829) 3 times weekly or intravenous ocrelizumab (600 mg; n = 827) every 24 weeks. Cognition was assessed with a Symbol Digit Modalities Test (SDMT), administered in written or oral form according to each site investigator's choice, that primarily measured cognitive processing speed at baseline and every 12 weeks until the end of the double-blind treatment (96 weeks). Treatment effects were investigated based on longitudinal linear models for the change from baseline in SDMT and Cox regression for the time to 12- or 24-week confirmed decline of ≥4 points.

RESULTS:

Among the participants with an SDMT assessment at baseline and ≥1 postbaseline time point (IFNβ-1a, n = 749; ocrelizumab, n = 766), ocrelizumab treatment was associated with a greater mean SDMT improvement over 96 weeks than IFNβ-1a treatment (5.4 [95 % CI, 4.4-6.5] vs 4.0 [95 % CI, 3.0-5.1]; adjusted mean difference, 1.4 [95 % CI, 0.05-2.72]; P = 0.042). The risk of a clinically meaningful SDMT decline (≥4 points) was lower for those treated with ocrelizumab for both ≥12 weeks (IFNβ-1a, 18.4 %; ocrelizumab, 12.7 %; hazard ratio, 0.63 [95 % CI, 0.47-0.85]; P = 0.003) and ≥24 weeks (IFNβ-1a, 12.9 %; ocrelizumab, 7.9 %; HR, 0.57 [95 % CI, 0.39-0.82]; P = 0.003).

CONCLUSION:

Ocrelizumab treatment resulted in better cognitive outcomes as measured by SDMT in participants with RMS compared with IFNβ-1a treatment. However, methodological limitations need to be considered when interpreting these data.

CLINICALTRIALS:

gov: NCT01247324, NCT01412333.

项与干扰素β-1a(Biogen, Inc.) 相关的新闻（医药）

2025-05-15

·PRNewswire

Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation. Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster." Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth. We look forward to their contributions and the positive impact that they will have on our organization." Founding members of Abzena's Scientific Advisory Board are: John Knight, Ph.D., is the founder of JKONSULT, a UK-based consulting firm, where he provides process chemistry and CMC consulting services for early-stage chemical development and transfer-to-plant projects, with a primary focus on material supplies for toxicological studies, Phase I, and Phase II clinical trials. Dr Knight has 38 years of pharmaceutical industry experience, with prior roles at GSK, Vernalis, and Evotec. Kamal Egodage, Ph.D., MBA, is the President of Lasanth® Consulting, where he provides consultation services for biologics that span from discovery through commercialization, including CMC development, regulatory strategy, interactions with health authorities, and corporate development strategy. Prior to establishing his consultancy in 2017, Dr. Egodage accumulated over 20 years of industry experience at Eli Lilly, Pharmacia, Monsanto, Symic Bio, and Novartis (Switzerland), where he was the Head of Strategy and Business Development for Biologics. Morris Rosenberg, D.Sc., is an independent consultant with over 25 years of experience in the development of therapeutic agents to treat a variety of human diseases. As a consultant, he provides advisory services to early research and clinical-stage companies on product development strategies for biologics, biosimilars, and ADC therapies. Prior to this, Dr Rosenberg played a key role in the development and commercialization of ADC-based therapies at Seattle Genetics and Immunomedics and participated in the development and launch of Trodelvy®, Adcetris®, Avonex®, Angiomax®, Xigris®, and Forteo®. Scott Rudge, Ph.D., co-founded RMC Pharmaceutical Solutions in 2004, which was acquired by Syner-G BioPharma Group in January 2023. He is a Principal Consultant with Syner-G, and leads its Commercial and Scientific Advisory Boards, and is a member of the Syner-G Board. He also currently serves as SVP of Product Development at Margaux Biologics, Head of CMC for Antidote Therapeutics and Optigo Biotherapeutics, is a Key Advisor to Jurata, and is an Adjunct Professor of Chemical Engineering at the University of Colorado. Dr Rudge has over 33 years of experience directing Process Engineering, Process Development, Product Development, and overall Pharmaceutical Operations, and has built and led several organizations in the biopharmaceutical industry. Steven Sandoval is the founder and serves as the CEO/ Operations Head of Pharmaceutical Technical Solutions, Inc. (PTSI). Providing technical oversight and client representative support to the Biotechnology, Gene Therapy, Viral Vector, Cell Therapy, T-CELL, CAR T, mRNA, 503a/ 503b Compounding, and Vaccine Pharmaceutical Industries since 2010. Prior to this, he held senior leadership roles at Pfenex Inc., Parsons (BMS), and Amgen. He has over 30 years of experience in biopharmaceutical manufacturing, operations, CMC tech transfer, engineering, facilities, and quality leadership services. Tatyana Touzova is the Chief Pharmaceutical Development & Manufacturing Officer at SERA Medicines, where she oversees CMC, regulatory, and nonclinical development from drug discovery through clinical stages. Prior to this, she held the position of Chief Operating Officer at AstralBio, AlmataBio, and ValenzaBio, where she directed CMC, manufacturing, and regulatory operations for multiple clinical-stage programs. She has over 35 years of experience in drug development, regulatory affairs, and commercial manufacturing of biologics and complex therapeutics and is recognized as an expert in CMC strategy, GMP compliance, and global regulatory submissions. About Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. Learn more at abzena.com. SOURCE Abzena WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购临床2期高管变更

2025-05-01

·Pharmaceutical Technology

Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

Spinal muscular atrophy treatment Spinraza (nusinersen) became Biogen’s best-selling drug in Q1 2025. Image credit: Shutterstock/ Tada Images. Biogen has unveiled Q1 2025 revenues above estimates, spurred by strong sales of rare disease assets amid a sales dropoff from its multiple sclerosis business. Quarterly revenues for the neurological disease drugmaker were $2.43bn, above analyst group William Blair’s estimates of $2.3bn. The Q1 sales performance represents a 6% increase compared to the same period in 2024, with Biogen ramping up commercial duties for existing drugs and buying assets during that time. One of those assets is Skyclarys, a drug picked up in a $7.3bn acquisition of Reata Pharmaceuticals in September 2023. The treatment for the neurodegenerative disorder Friedreich’s ataxia generated revenue of $124m in Q1, a value that had already taken into account the impact seen in US sales due to Medicare discount dynamics. Approved in the US, Europe, and UK, amongst others, Skyclarys has a high growth ceiling. GlobalData’s Pharma Intelligence Centre forecasts sales of $1.3bn by 2031. GlobalData is the parent company of Pharmaceutical Technology . Skyclarys is one of the drugs spurring a change of the guard in Biogen’s pipeline. The company is well known for its host of multiple sclerosis treatments, such as Vumerity (diroximel fumarate), Tysabri (natalizumab), and Avonex (interferon beta-1a). But, sales for these treatments have declined over the years as biosimilars entered the market. The company’s multiple sclerosis business shrank 11% in Q1 2025 compared to the same period last year. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence “Biogen is really, a tale of two companies in my view. There’s one company which has been a multiple sclerosis company, and that portfolio, as you all know, has been gradually declining,” said Biogen’s CEO Chris Vibacher in a Q1 earnings call. “But there’s a new Biogen emerging. And when I look at the rare disease business […] we actually have a commercial portfolio that we’re actively promoting that’s now gotten to be about 45% of our product revenue. And those products mostly have a very long runway to continue to grow,” Vibacher added. Alongside Skyclarys, Biogen’s rare disease business is headed by spinal muscular atrophy treatment Spinraza (nusinersen). Spinraza generated global Q1 2025 sales of $423.9m, up from $341.3m in Q1 2024. This increase, coupled with the decline of Tysabri, meant Spinraza was Biogen’s best-selling drug in Q1 2025. Leqembi’s “modest growth” Another key part of Biogen’s business model is its Alzheimer’s segment, now solely headed by Leqembi (lecanemab) after the company discontinued Aduhelm (aducanumab) at the start of 2024. Biogen splits revenue from Leqembi with co-developer Eisai equally, the latter reporting Q1 sales of $96m for the drug. The US, where Leqembi got a full approval in July 2023, accounted for $52m of those sales. Biogen has already secured key milestones for Leqembi this year. In January, the US Food and Drug Administration (FDA) approved maintenance dosing of Leqembi, a move expected to expand its market share. Then in April, the Leqembi was authorised for use in the European Union (EU). Biogen said the Q1 sales for Leqembi represented “continued sequential growth.” William Blair analyst Myles R. Minter said in a research note that: “Skyclarys had a strong quarter, but the commercial focus remains on Leqembi, which has seen only modest growth, in our view.” In the mergers and acquisitions space, Biogen failed a $469m takeover bid of Sage Therapeutics in January.

上市批准并购生物类似药

2025-03-31

·GBIHealth

卫健委：2025年底全面停止收取门诊预交金

药械追踪No.1 / 罗氏罗可适在华获批，治疗复发型和原发进展型多发性硬化症2025年3月31日，罗氏宣布，奥瑞利珠单抗注射液（商品名：罗可适/Ocrevus）已正式获得中国国家药品监督管理局（NMPA）批准，每六个月静脉输注一次给药，用于治疗成人复发型多发性硬化症（RMS，包括临床孤立综合征、复发缓解型多发性硬化和活动性继发进展型多发性硬化）和成人原发进展型多发性硬化症（PPMS）。多发性硬化症（MS）是一种中枢神经系统炎性疾病，患者体内免疫系统异常攻击中枢神经系统，导致中枢神经系统神经细胞的髓鞘发生炎症和损伤。其中RMS病程反复发作，最终可能导致永久性残疾；PPMS自发病开始，病情会持续进展恶化，患者运动、感觉和认知功能持续下降。奥瑞利珠单抗可通过靶向CD20阳性B细胞实现MS疾病修正，此前已在全球100多个国家和地区获批，并被多项权威指南列为MS标准治疗方案。针对RMS的两项随机、双盲、双模拟、阳性药物对照III期临床试验OPERA I和OPERA II结果显示，与干扰素β-1a治疗相比，奥瑞利珠单抗可以显著降低患者的年复发率（ARR）及致残比例（12周确认残疾进展CDP的患者比例）。针对PPMS的随机、双盲、安慰剂对照临床试验ORATORIO结果显示，与安慰剂组相比，患者接受奥瑞利珠单抗治疗可以显著降低12周CDP风险约24%（p=0.0321），达到主要终点。奥瑞利珠单抗此次在中国获批，将为中国MS患者提供全球先进的全新治疗选择。->点击文末阅读原文，解锁完整双语新闻No.2 / 赛诺菲血友病新药fitusiran及西门子伴随诊断在美获批2025年3月28日，赛诺菲宣布，美国食品药品监督管理局（FDA）已批准Qfitlia（fitusiran）作为常规预防治疗，用于伴或不伴凝血因子VIII或IX抑制物的血友病A或B成人患者和≥12岁青少年患者，以预防或减少其出血频率。Fitusiran注射液是首个降低抗凝血酶（一种抑制血液凝固的蛋白质）的血友病疗法，采用小分子干扰RNA技术，能够实现低频次治疗、皮下给药和低容量注射。Fitusiran此次获批基于III期ATLAS研究的积极数据。该研究显示，无论血友病患者是否存在抑制物，fitusiran均可实现年化出血率（ABR）指标具有临床意义的改善，发挥出色的出血预防效果，且每年仅需注射六次。在中国，Fitusiran注射液于2024年11月被纳入国家药品监督管理局药品审评中心《以患者为中心的罕见疾病药物研发试点工作计划（“关爱计划”）》试点项目；其在中国的上市申请预计将在2025年下半年收到监管决定。随着fitusiran的获批，FDA还同步批准了西门子医疗的INNOVANCE抗凝血酶检测作为fitusiran的伴随诊断，用于测量抗凝血酶水平。->点击文末阅读原文，解锁完整双语新闻企业动态No.1 / 卫材质子泵抑制剂波利特中国权益7.25亿元转让顶峰生物2025年3月28日，日本卫材制药宣布将其质子泵抑制剂波利特（雷贝拉唑钠肠溶片）的中国权益转让给康桥资本控股的北京顶峰生物医药有限公司（简称“顶峰生物”）。根据协议条款，卫材将获得7.25亿元人民币预付款，以及潜在的销售里程碑付款。目前顶峰生物已开始销售活动，卫材将在过渡期间管理波利特的生产制造和营销授权的转让。波利特是一款质子泵抑制剂，广泛应用于治疗胃溃疡、十二指肠溃疡、吻合口溃疡、反流性食管病以及卓-艾氏综合征等消化系统疾病。该产品2000年进入中国，快速放量并成为当时卫材中国的增长引擎。进入第九批集采后，该产品大幅降价。->点击文末阅读原文，解锁完整双语新闻No.2 / 恒瑞医药2024年财报：收入279.85亿元，创新药销售收入增长30.6%2025年3月30日，恒瑞医药（600276.SH）发布2024年财务业绩。2024年公司营业收入279.85亿元，同比增长22.63%。归母净利润63.37亿元，同比增长47.28%。创新药销售收入138.92亿元，同比增长30.6%。2024年，公司共有9项创新成果落地，包括4款1类新药获批上市：泰吉立定、夫那奇珠单抗、瑞卡西单抗和艾玛昔替尼，以及5项新适应证获批上市：氟唑帕利卵巢癌和乳腺癌适应证、阿帕替尼乳腺癌适应证、恒格列净糖尿病适应证以及泰吉立定用于术后中重度疼痛适应证。预计2025~2027年，公司分别有11项、13项和23项新药/新适应证获批上市。->点击文末阅读原文，解锁完整双语新闻No.3 / 绿叶制药2024年财报：产品销售收入56.9亿元2024年3月30日，绿叶制药（2186.HK）发布2024年财务业绩。报告期内，集团录得总收入60.61亿元，同比下降1.3%。总收入下降主要由非产品销售（如研发服务）收入下降导致。产品销售额56.895亿元，同比增长1.1%。于中国市场，集团主要产品均于其四大主要治疗领域（肿瘤科、中枢神经系统、心血管及代谢）具竞争地位。国际市场，集团的产品主要定位于中枢神经系统治疗领域，包括思瑞康和思瑞康缓释片、Erzofri、Rykindo、利斯的明单日透皮贴剂、利斯的明多日透皮贴剂、芬太尼贴剂及丁丙诺啡贴剂。报告期内，集团中枢神经系统治疗领域产品销售额减少4.8%，达16.13亿元。肿瘤治疗领域产品销售额减少1.8%，达20.846亿元。心血管系统治疗领域产品销售额减少1.6%，达16.6亿元。代谢治疗领域产品销售额下降13.7%，达人民币3.9亿元。->点击文末阅读原文，解锁完整双语新闻行业政策No.1 / 中保协发布商保药品目录A系初稿并征求意见2025年3月28日，中国保险行业协会（简称“中保协”）就商业健康保险药品目录-A系（简称“商保药品目录-A系”）初稿，并面向各健康险专委会常委单位征求意见。中保协曾在2025年2月组织召开座谈会，旨在集中行业资源构建全覆盖、多层次的商保药品目录体系，建立健全ABCDE目录体系，基于不同客群依次完善A系-惠民保产品、B系-百万医疗险产品、C系-中端医疗险产品等目录建设，逐步将医保目录外药品扩展覆盖至境内外药监局审批上市的所有药品（保留负面清单权利），给予消费者更加自由的选择权。商保药品目录建设工作首发聚焦“A系”目录，工作组统计了 29个省、自治区、直辖市的城市定制型商业医疗保险（又称“惠民保”）产品，在各产品中已覆盖的《国家基本医疗、工伤保险和生育保险药品目录》基础上，针对其中2619种特定药品目录，按照高频原则排序，同时与保费总量大、覆盖人群广的重点省、自治区、直辖市产品情况进行比照，梳理形成商保药品目录-A系初稿，共包括30款药品、涉及19种适应证。下一阶段，工作组将在现行A系目录基础上，逐步建立、完善商保药品目录形成机制和动态调整机制，结合行业建议不断优化、推进不同层级目录建设，同时将持续推动保险、医药、医院等相关方协同，推进药品入院、医疗险直赔快赔等相关工作有序开展。->点击阅读原文，解锁完整双语新闻No.2 / 卫健委：2025年底全面停止收取门诊预交金2025年3月28日，卫健委发布《关于规范公立医疗机构预交金管理工作的通知》，要求自2025年3月31日起，公立医疗机构要全面停止收取门诊预交金，2025年12月31日前完成存量门诊预交金的资金清算、退款，同时降低住院预交金额度。预交金指的是患者在门诊或者办理住院之前，需要预先支付的一笔押金，以作为后续治疗费用的保障，也是公立医院传统的收费方式。二十世纪80年代，为了减少患者排队次数、缩短缴费等候时间，医疗机构相继设立了住院预交金和门诊预交金。此前，已有多地取消了门诊预交金，此次为全国公立医疗机构全面取消，并限时清退患者已缴纳的门诊预交金。同时，降低住院预交金额度，参考同病种前3年度实际发生的次均住院费用和个人自付费用，合理确定住院预交金额度，医保患者住院预交金额度降至同病种同保障类别个人自付平均水平，自2025年6月30日起执行。->点击阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ xujingou@baidu.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

siRNA上市批准临床3期临床结果ASH会议

100 项与干扰素β-1a(Biogen, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04554	干扰素β-1a(Biogen, Inc.)	L03AB07	DB00060

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
继发进展型多发性硬化	澳大利亚	Biogen Australia Pty Ltd.	2004-05-04
复发性多发性硬化	欧盟	Biogen Netherlands BV	1997-03-13
复发性多发性硬化	冰岛	Biogen Netherlands BV	1997-03-13
复发性多发性硬化	列支敦士登	Biogen Netherlands BV	1997-03-13
复发性多发性硬化	挪威	Biogen Netherlands BV	1997-03-13
多发性硬化症	美国	Biogen, Inc.	1996-05-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
溃疡性结肠炎	临床2期	美国	Biogen, Inc.	2008-05-01
溃疡性结肠炎	临床2期	加拿大	Biogen, Inc.	2008-05-01
溃疡性结肠炎	临床2期	捷克	Biogen, Inc.	2008-05-01
溃疡性结肠炎	临床2期	匈牙利	Biogen, Inc.	2008-05-01
溃疡性结肠炎	临床2期	波兰	Biogen, Inc.	2008-05-01
溃疡性结肠炎	临床2期	俄罗斯	Biogen, Inc.	2008-05-01
溃疡性结肠炎	临床2期	斯洛伐克	Biogen, Inc.	2008-05-01
慢性炎症性脱髓鞘性多发性神经病	临床2期	美国	Biogen, Inc.	2004-02-01
慢性炎症性脱髓鞘性多发性神经病	临床2期	澳大利亚	Biogen, Inc.	2004-02-01
慢性炎症性脱髓鞘性多发性神经病	临床2期	加拿大	Biogen, Inc.	2004-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NPMSC (AAN2024)	N/A	-	254	Avonex	壓襯蓋築簾憲構範夢齋(鹹鏇窪獵顧餘築醖積製) = 廠壓願鏇範選鑰網衊艱餘製遞範繭餘選鏇衊衊 (觸遞積鏇餘糧積餘憲齋 ) 更多	积极	2024-04-09
				Plegridy	壓襯蓋築簾憲構範夢齋(鹹鏇窪獵顧餘築醖積製) = 鬱鑰構築遞壓觸網選網餘製遞範繭餘選鏇衊衊 (觸遞積鏇餘糧積餘憲齋 ) 更多
PeMSDD (ACTRIMS2024)	N/A	-	254	Avonex	顧鏇餘衊窪簾淵鏇獵鹽(蓋齋膚顧製窪蓋範廠鹹) = 鑰餘願簾鹹壓衊糧積鑰壓廠積製淵繭鏇積淵艱 (觸鹽獵餘夢糧憲範窪膚 ) 更多	积极	2024-03-01
				Plegridy	顧鏇餘衊窪簾淵鏇獵鹽(蓋齋膚顧製窪蓋範廠鹹) = 積壓網鹹鹽餘構願窪遞壓廠積製淵繭鏇積淵艱 (觸鹽獵餘夢糧憲範窪膚 ) 更多
ACTRIMS2023	N/A	多发性硬化症	-	Interferon beta-1a	窪積獵簾願壓簾壓壓壓(壓齋願糧齋糧願膚蓋鬱) = congestive heart failure 製壓夢膚築簾窪顧艱鹹 (壓膚衊膚選積鏇構製鬱 ) 更多	不佳	2023-05-30
AAN2022	N/A	多发性硬化症	-	Subcutaneous Interferon β-1a	構糧築顧繭範鹽鬱糧遞(齋鬱憲構獵築遞鹽繭衊) = the majority were non-serious events. Among confirmed cases (n=1029), 110 patients were hospitalized with 5 requiring mechanical ventilation. There were 24 fatalities (18 fatal COVID-19 events and 6 other fatalities unconfirmed for COVID-19 involvement). At time of reporting, around half of COVID-19 confirmed AEs were recovered or resolving. 顧夢鹹膚觸構願齋製繭 (築製夢衊襯構遞壓選製 ) 更多	-	2022-05-03
REFLEX/ION study (ECTRIMS2021)	N/A	脱髓鞘疾病	392	Early treatment with subcutaneous interferon beta-1a	鏇襯壓糧醖膚築選範淵(獵艱醖艱壓鏇繭鬱鑰範) = 蓋淵艱製膚選鬱壓顧範獵蓋衊觸醖窪鏇範積壓 (獵鬱鑰築膚餘襯蓋鏇鬱 ) 更多	-	2021-10-12
				Delayed treatment with subcutaneous interferon beta-1a	鏇襯壓糧醖膚築選範淵(獵艱醖艱壓鏇繭鬱鑰範) = 壓醖淵築製窪憲醖繭憲獵蓋衊觸醖窪鏇範積壓 (獵鬱鑰築膚餘襯蓋鏇鬱 ) 更多
ACTRIMS2021	N/A	多发性硬化症	-	Subcutaneous Interferon Î²-1a	齋膚網積簾壓範鑰憲簾(淵鏇餘積製餘衊廠醖鹽) = Cumulative to August 4, 2020, there was no increased risk of COVID-19 in sc IFN Î²-1a-treated patients with RMS and cases were relatively mild, consistent with previously reported registries. 餘願構網艱艱夢鑰願願 (淵範壓壓顧觸艱繭糧觸 ) 更多	积极	2021-07-01
ECTRIMS2020	N/A	多发性硬化症	-	Subcutaneous interferon β-1a	範願顧廠壓構餘蓋齋製(製鏇淵觸願觸積餘遞製) = 23 cases of confirmed COVID-19 in sc IFN β-1a treated MS patients 積壓遞築繭鑰糧遞鬱簾 (積廠積憲鏇範膚壓艱壓 ) 更多	积极	2020-12-07
ECTRIMS2020	N/A	多发性硬化症	-	subcutaneous interferon beta-1a (18-30 years)	構範鏇餘淵遞網憲蓋膚(觸廠鹹構壓遞襯憲鹽鹹) = 餘醖窪顧鑰鬱膚廠夢餘鏇窪膚夢壓鹹艱壓構網 (構齋構製餘繭遞遞繭顧, 0.16 ~ 0.34) 更多	-	2020-12-07
				subcutaneous interferon beta-1a (31-40 years)	-
EAN2020	N/A	多发性硬化症	-	Subcutaneous Interferon-beta1a (Rebif 22Âµg and 44Âµg)	選壓願糧壓膚鹽築鏇餘(顧觸觸鏇夢憲齋窪窪壓) = 齋觸淵襯窪簾繭鹹膚膚襯繭範積餘遞醖積艱築 (製遞衊廠淵壓網顧觸窪 )	-	2020-05-22
				Intramuscular Interferon-beta1a (Avonex)	選壓願糧壓膚鹽築鏇餘(顧觸觸鏇夢憲齋窪窪壓) = 鹽壓網範夢鏇襯鏇艱艱襯繭範積餘遞醖積艱築 (製遞衊廠淵壓網顧觸窪 )
REFLEX (AAN2020)	临床3期	脱髓鞘疾病一线 cerebrospinal fluid specific oligoclonal bands \| symptomatic lesions \| cortical lesions	517	scIFNβ-1a three times (tiw)	餘製艱簾網窪蓋膚淵糧(簾積構觸網窪鹽簾窪窪) = 窪構餘糧襯餘壓淵夢夢願齋遞範淵鹽鏇遞觸夢 (網襯窪願鏇鹽齋鑰鏇鑰 )	积极	2020-04-14
				scIFNβ-1a once weekly (qw)	餘製艱簾網窪蓋膚淵糧(簾積構觸網窪鹽簾窪窪) = 醖繭艱醖繭廠鑰鬱醖憲願齋遞範淵鹽鏇遞觸夢 (網襯窪願鏇鹽齋鑰鏇鑰 )